BillionToOne posted a sharp Q1 revenue increase of 84% year over year, driven by higher prenatal clinical testing volume and faster growth in oncology assays. The company reported Q1 2026 revenue of $108.4 million, compared with $59.0 million in the prior-year quarter. Prenatal testing revenue totaled $96.5 million, and BillionToOne also pointed to oncology testing revenue rising roughly fivefold. The company logged 189,000 tests in Q1 and delivered 188,000 tests in the recently completed quarter, both representing large year-over-year gains. BillionToOne additionally launched Unity Confirm, a circulating fetal cell-based, non-invasive assay intended to confirm high-risk screening results without proceeding to invasive procedures such as CVS or amniocentesis. The company framed the product as an effort to reduce risk while improving confirmation workflows. Management raised full-year 2026 revenue guidance to $450 million–$465 million, reflecting 50% growth at the midpoint. The quarter improved profitability, with net income of $18.0 million, versus a net loss a year earlier.